TWF2 and renal cell carcinoma: Despite its clinical utility, ≈60–70% of patients with metastatic RCC exhibit intrinsic resistance to sunitinib, and even those who initially respond frequently relapse within 11 months of treatment.[87] This study demonstrated that depletion of TWF2 enhances sensitivity to sunitinib, indicating that TWF2 may serve as a promising therapeutic target in RCC.